alexa Shichang Miao | ChemoCentryx Inc
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
 
 

Shichang Miao

Senior Director
Biography

Shichang Miao, Ph.D., is a past president of CABS (2009-2010). He is employed as Senior Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc., a public biotech company focusing on the drug discovery and development through regulation of chemokine receptors. Previously, he was a director in the pharmacokinetics and drug metabolism department at Amgen South San Francisco. He worked at Tularik Inc. from 1994 through 2004 (most recently as Associate Director, Analytical Chemistry and Drug Metabolism) until Tularik's acquisition by Amgen. He holds a Ph.D. in organic chemistry / natural products chemistry from the University of British Columbia (Vancouver) and carried out postdoctoral research in organic chemistry and biochemistry. In addition to his CABS leadership activities, he is also the founder and president of CACO Pharmaceutical & BioScience Society (CACO-PBS), a professional organization of 3000+ members with chapters in the San Francisco Bay Area and San Diego. CACO Workshop Metabolite Detection and Identification: StrategiesTechniques and Case Studies -2012-06-18 | Bio2Device Group
www.Bio2DeviceGroup.org, 15 May 2012 Speakers: Bill Fitch, Mingshe Zhu (BMS), Shichang Miao (ChemoCentryx), Deepak Dalvie (Pfizer), Shuguang Ma (Genentech)

Research Interest

complications of hyperglycemia, advanced type 2 diabetes treatment, Type 2 diabetes, Chemokine Receptor 2 (CCR2); CCR2 antagonist; MCP- 1; Chemokine; Chemokine receptor; 

Publications

Orally-Administered Chemokine Receptor CCR2 Antagonist CCX140-B in Type 2 Diabetes: A Pilot Double-Blind, Randomized Clinical Trial

Markolf Hanefeld, Ernest Schell, Ioanna Gouni-Berthold, Martin Melichar, Ivana Vesela, Dan Johnson, Shichang Miao, Tim J Sullivan, Juan C Jaen, Thomas J Schall, Pirow Bekker and The CCX140-B Diabetes Study Group

Research Article: J Diabetes Metab 2012, 3:225

Global Speakers in the subject

Global Experts in the subject

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords